Charnes Chiu, MD
Nephrology · Santa Fe, NMNPI 1548290869
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 25.7% of the total.
Across 107 payments — averaging $21.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$599
- Bayer$503
- Vifor Pharma, Inc.$237
- Amgen$149
- Ardelyx, Inc.$125
- Otsuka America Pharmaceutical, Inc.$115
- plus $600 from 15 others
What the payments were for
- Food & beverage$2,328100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 27 | $599 |
| Bayer | 23 | $503 |
| Vifor Pharma, Inc. | 11 | $237 |
| Amgen | 6 | $149 |
| Ardelyx, Inc. | 5 | $125 |
| Otsuka America Pharmaceutical, Inc. | 6 | $115 |
| Boehringer Ingelheim | 4 | $81 |
| GSK | 4 | $81 |
| Fresenius USA Marketing, Inc. | 4 | $72 |
| Aurinia Pharma U.S., Inc. | 3 | $69 |
| Novartis | 2 | $42 |
| Outset Medical Inc | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 2 | $29 |
| Novo Nordisk | 1 | $28 |
| Calliditas Therapeutics US Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Cormedix Inc. | 1 | $25 |
| Travere Therapeutics, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Nxstage Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,328 in reported general payments places this provider in the 60th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 11 | $42,323 |
| KerendiaFinerenone | 36 | $20,254 |
| Sevelamer Carbonate | 40 | $16,198 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $9,905 |
| Sevelamer Hcl | 14 | $5,849 |
| Potassium Citrate ErPotassium Citrate | 51 | $5,371 |
| Calcium Acetate | 20 | $2,454 |
| Hydralazine Hcl | 131 | $2,277 |
| Amlodipine Besylate | 150 | $1,432 |
| Carvedilol | 133 | $1,258 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 55 | $1,080 |
| Metoprolol Succinate | 39 | $858 |
| Febuxostat | 15 | $788 |
| Tamsulosin Hcl | 37 | $635 |
| Nifedipine ErNifedipine | 31 | $577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $72 | $42,32311 claims |
| BayerKerendia | $503 | $20,25436 claims |
| AstraZenecaLokelma | $599 | $9,90524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 68 nephrology providers in New Mexico.
Other nephrology in Santa Fe
- Catalina VoinescuSanta Fe$41K
- Tudor OcneanuSanta Fe$6K
- Alexandra VoinescuSanta Fe$4K
- William Vasquez EspinosaSanta Fe$1K
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- Jose HenaoLas Cruces$31K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.